220 related articles for article (PubMed ID: 18781678)
1. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
Schapira AH
Mov Disord; 2008; 23 Suppl 3():S515-20. PubMed ID: 18781678
[TBL] [Abstract][Full Text] [Related]
2. Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
4. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [Abstract][Full Text] [Related]
5. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Ziv I; Zilkha-Falb R; Offen D; Shirvan A; Barzilai A; Melamed E
Mov Disord; 1997 Jan; 12(1):17-23. PubMed ID: 8990049
[TBL] [Abstract][Full Text] [Related]
6. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
7. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
8. Treatment of early Parkinson's disease. Part 1.
Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
[TBL] [Abstract][Full Text] [Related]
9. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
10. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress.
Mytilineou C; Walker RH; JnoBaptiste R; Olanow CW
J Pharmacol Exp Ther; 2003 Feb; 304(2):792-800. PubMed ID: 12538835
[TBL] [Abstract][Full Text] [Related]
11. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
12. [Ropinirole in the treatment of Parkinson's disease: an update].
Vivancos-Matellano F
Rev Neurol; 2006 May 1-15; 42(9):542-8. PubMed ID: 16676278
[TBL] [Abstract][Full Text] [Related]
13. Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?
Murer MG; Raisman-Vozari R; Gershanik O
Drug Saf; 1999 Nov; 21(5):339-52. PubMed ID: 10554050
[TBL] [Abstract][Full Text] [Related]
14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
15. Treatment of early Parkinson's disease. Part 2.
Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
[TBL] [Abstract][Full Text] [Related]
16. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
17. The protective role of levodopa in the human substantia nigra.
Rajput AH
Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992
[TBL] [Abstract][Full Text] [Related]
18. [Early treatment of Parkinson's disease with levodopa].
Odekerken VJ; Post B; Verschuur CV; de Bie RM
Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
[TBL] [Abstract][Full Text] [Related]
19. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
